Study identifier:1839IL/0151
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I/II trial of ZD1839 (Iressa) given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer
Head and Neck Neoplasms
Phase 1/2
No
Gefitinib, Cisplatin
All
40
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|